No Data
No Data
October 15th [Today's Investment Strategy]
[Fisco Selected Stock] [Material Stock] Cosmos Pharmaceuticals <3349> 7320 yen (10/11) A drugstore based in Kyushu. They announced their first quarter results. Operating profit increased by 28.8% year-on-year to 11.5 billion yen. Despite a temporary decline in profitability due to in-house competition, they carried out new store openings and expanded their store network to new business territories without hesitation. The operating profit for the fiscal year ending in May 2025 is expected to be 31.6 billion yen, a 0.3% increase from the previous period. The progress rate for the first quarter compared to the full-year forecast is 36.6%. The full-year forecast is for a slight increase in profit.
Steady, supported by high U.S. stock prices, but the upside is a heavy development.
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to show a firm development. In the Tokyo market, the Dow Jones Inc rose by 409.74 points (+0.97%) in the U.S. stock market on the 11th, the last weekend of the 3-day holiday. The market was supported by positive earnings from banks and expectations for major corporate earnings. Moreover, the Producer Price Index (PPI) results did not significantly alter the trajectory for interest rate cuts for the rest of the year, providing a sense of reassurance. Yesterday, the market continued to rise by $201.36 (+0.47%) to reach 43,065.22 points.
Ryohin Keikaku, operating profit up by 69.4% to 56.1 billion yen on August 24, financial estimates for August 25 showing a 2.0% decrease to 55 billion yen.
Ryohin Keikaku <7453> announced its financial results for the August 2024 period, with operating revenue increasing by 13.8% year-on-year to 661.677 million yen, and operating profit increasing by 69.4% to 56.135 million yen. Both operating revenue and each stage profit reached record highs. The improvement in operating gross profit margin was due to the effects of domestic price adjustments and the suppression of price reductions. For the August 2025 period, operating revenue increased by 10.9% year-on-year to 734 billion yen, while operating profit decreased by 2% to 55 billion yen.
Shikigaku, the Institute of Immunobiology, and others [Emerging Markets Press Release]
<138A> Hikari Food Service downward revision, this term's operating profit outlook 20.2 billion yen ← 31.2 billion yen <2981> Lendix subsidiary established and new business initiated <4570> Immunobiology Research Institute acquires patent for 'Anti-HIV antibody and method of manufacturing' <4881> Roche initiates joint research with Fanpep on vaccine adjuvant for antibody-directed peptide <5591> Avilen engages in entrusted development of AI-related systems such as LangCo
SHIKIGAKU Co. Achieves Profitable Growth Mid-Year
SHIKIGAKU Forecasts Strong Profit Gains in FY2/25
No Data
No Data